Radha Rajasingham1, Eva A Enns2, Alexander Khoruts3, Byron P Vaughn3. 1. Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota. 2. Division of Health Policy and Management, University of Minnesota School of Public Health. 3. Division of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis.
Abstract
BACKGROUND: In 2018, the Infectious Diseases Society of America (IDSA) published guidelines for diagnosis and treatment of Clostridioides (formerly Clostridium) difficile infection (CDI). However, there is little guidance regarding which treatments are cost-effective. METHODS: We used a Markov model to simulate a cohort of patients presenting with an initial CDI diagnosis. We used the model to estimate the costs, effectiveness, and cost-effectiveness of different CDI treatment regimens recommended in the recently published 2018 IDSA guidelines. The model includes stratification by the severity of the initial infection, and subsequent likelihood of cure, recurrence, mortality, and outcomes of subsequent recurrences. Data sources were taken from IDSA guidelines and published literature on treatment outcomes. Outcome measures were discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS: Use of fidaxomicin for nonsevere initial CDI, vancomycin for severe CDI, fidaxomicin for first recurrence, and fecal microbiota transplantation (FMT) for subsequent recurrence (strategy 44) cost an additional $478 for 0.009 QALYs gained per CDI patient, resulting in an ICER of $31 751 per QALY, below the willingness-to-pay threshold of $100 000/QALY. This is the optimal, cost-effective CDI treatment strategy. CONCLUSIONS: Metronidazole is suboptimal for nonsevere CDI as it is less beneficial than alternative strategies. The preferred treatment regimen is fidaxomicin for nonsevere CDI, vancomycin for severe CDI, fidaxomicin for first recurrence, and FMT for subsequent recurrence. The most effective treatments, with highest cure rates, are also cost-effective due to averted mortality, utility loss, and costs of rehospitalization and/or further treatments for recurrent CDI.
BACKGROUND: In 2018, the Infectious Diseases Society of America (IDSA) published guidelines for diagnosis and treatment of Clostridioides (formerly Clostridium) difficile infection (CDI). However, there is little guidance regarding which treatments are cost-effective. METHODS: We used a Markov model to simulate a cohort of patients presenting with an initial CDI diagnosis. We used the model to estimate the costs, effectiveness, and cost-effectiveness of different CDI treatment regimens recommended in the recently published 2018 IDSA guidelines. The model includes stratification by the severity of the initial infection, and subsequent likelihood of cure, recurrence, mortality, and outcomes of subsequent recurrences. Data sources were taken from IDSA guidelines and published literature on treatment outcomes. Outcome measures were discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS: Use of fidaxomicin for nonsevere initial CDI, vancomycin for severe CDI, fidaxomicin for first recurrence, and fecal microbiota transplantation (FMT) for subsequent recurrence (strategy 44) cost an additional $478 for 0.009 QALYs gained per CDI patient, resulting in an ICER of $31 751 per QALY, below the willingness-to-pay threshold of $100 000/QALY. This is the optimal, cost-effective CDI treatment strategy. CONCLUSIONS: Metronidazole is suboptimal for nonsevere CDI as it is less beneficial than alternative strategies. The preferred treatment regimen is fidaxomicin for nonsevere CDI, vancomycin for severe CDI, fidaxomicin for first recurrence, and FMT for subsequent recurrence. The most effective treatments, with highest cure rates, are also cost-effective due to averted mortality, utility loss, and costs of rehospitalization and/or further treatments for recurrent CDI.
Authors: Thomas J Louie; Mark A Miller; Kathleen M Mullane; Karl Weiss; Arnold Lentnek; Yoav Golan; Sherwood Gorbach; Pamela Sears; Youe-Kong Shue Journal: N Engl J Med Date: 2011-02-03 Impact factor: 91.245
Authors: Oliver A Cornely; Derrick W Crook; Roberto Esposito; André Poirier; Michael S Somero; Karl Weiss; Pamela Sears; Sherwood Gorbach Journal: Lancet Infect Dis Date: 2012-02-08 Impact factor: 25.071
Authors: Maria C Mora Pinzon; Ronald Buie; Jinn-Ing Liou; Daniel K Shirley; Charlesnika T Evans; Swetha Ramanathan; Linda Poggensee; Nasia Safdar Journal: Clin Infect Dis Date: 2019-04-08 Impact factor: 9.079
Authors: Colleen R Kelly; Alexander Khoruts; Christopher Staley; Michael J Sadowsky; Mortadha Abd; Mustafa Alani; Brianna Bakow; Patrizia Curran; Joyce McKenney; Allison Tisch; Steven E Reinert; Jason T Machan; Lawrence J Brandt Journal: Ann Intern Med Date: 2016-08-23 Impact factor: 25.391